Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03990883 · ClinicalTrials.gov registry record · NA

Effectiveness and Safety of Princess FILLER Lidocaine in Correction of Nasolabial Folds (NLF)

A NA study of Dermatological Non-Disease, sponsored by Croma-Pharma.

Completed
Registry status
NA
Development phase
295
Enrollment target
11
Study locations

NCT03990883 is a NA study of Dermatological Non-Disease that has completed, run by Croma-Pharma. The registered enrollment target is 295 participants. The trial reports 11 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03990883, a NA study of Dermatological Non-Disease, has completed, sponsored by Croma-Pharma.

COMPLETED
Registry status
NA
Development phase
295 participants
Enrollment target
11
Study locations

Study Summary

Clinical Investigation to demonstrate the effectiveness and safety of Princess Filler Lidocaine in the correction of moderate to severe nasolabial folds

Conditions Studied

Interventions

  • DEVICE Princess Filler Lidocaine

Study Locations (11)

California

  • John Joseph - Beverly Hills
  • Sabrina Fabi - San Diego
  • Ava Shamban - Santa Monica

Alabama

  • Gary Monheit - Birmingham

Colorado

  • Joel Cohen - Greenwood Village

Florida

  • Jeremy Green - Coral Gables

Maryland

  • Robert Weiss - Hunt Valley

New Jersey

  • Jeanine Downie - Montclair

New York

  • The Center for Dermatology Cosmetic and Laser Surgery - New York

Pennsylvania

  • Susan Taylor - Philadelphia

Trial Details

FieldValue
Enrollment Target 295 participants
Start Date 2019-06-04
Est. Completion 2022-02-15
Phase NA

Sponsor

Croma-Pharma

6 total trials

What the Registry Record Tells You About NCT03990883

The ClinicalTrials.gov registry entry for NCT03990883 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 295 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Croma-Pharma, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dermatological Non-Disease appearing as the primary indexed condition, and to 1 intervention - of which Princess Filler Lidocaine is the first listed.

NCT03990883 reports 11 study locations spanning 9 distinct geographic areas - top geographies include California, Alabama, Colorado.

Frequently Asked Questions

What is clinical trial NCT03990883 about?

NCT03990883 is a clinical study titled "Effectiveness and Safety of Princess FILLER Lidocaine in Correction of Nasolabial Folds (NLF)". Clinical Investigation to demonstrate the effectiveness and safety of Princess Filler Lidocaine in the correction of moderate to severe nasolabial folds

What is the current status of trial NCT03990883?

This trial is currently completed. It is a NA study. The enrollment target is 295 participants. The study started on 2019-06-04. Estimated completion is 2022-02-15.

What conditions does trial NCT03990883 study?

This clinical trial studies the following conditions: Dermatological Non-Disease.

What interventions are being tested in trial NCT03990883?

The interventions under investigation include: Princess Filler Lidocaine (DEVICE).

Who is sponsoring clinical trial NCT03990883?

This trial is sponsored by Croma-Pharma, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03990883 being conducted?

This trial has 11 study locations across Alabama, California, Colorado, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dermatological Non-Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.